hVIVO (LON:HVO) Trading Down 3.3% Following Analyst Downgrade

Key Points

• hVIVO's stock price decreased by 3.3% after Shore Capital downgraded its price target from GBX 35 to GBX 25, although the firm maintains a buy rating on the stock.
• The trading volume for hVIVO surged, with 7,687,127 shares exchanged, marking a 164% increase from the average session volume.
• Analysts have a consensus buy rating for hVIVO, with an average target price of GBX 23, while Peel Hunt recently reiterated an "add" rating with a GBX 21 price target.

hVIVO plc (LON:HVO - Get Free Report)'s stock price fell 3.3% during trading on Wednesday after Shore Capital lowered their price target on the stock from GBX 35 to GBX 25. Shore Capital currently has a buy rating on the stock. hVIVO traded as low as GBX 8.30 ($0.11) and last traded at GBX 8.70 ($0.12). 7,687,127 shares were traded during trading, an increase of 164% from the average session volume of 2,914,998 shares. The stock had previously closed at GBX 9 ($0.12).

Separately, Peel Hunt reiterated an "add" rating and set a GBX 21 price target on shares of hVIVO in a research report on Tuesday, July 29th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of GBX 23.

hVIVO Stock Performance

The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm has a market cap of £57.73 million, a price-to-earnings ratio of 541.94 and a beta of 0.97. The stock has a fifty day moving average price of GBX 9.98 and a 200 day moving average price of GBX 12.79.

hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.